Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) shares shot up 11.3% on Wednesday. The stock traded as high as $4.09 and last traded at $4.2730. Approximately 260,194 shares were traded during mid-day trading, a decline of 92% from the average session volume of 3,383,160 shares. The stock had previously closed at $3.84.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on PRME. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a report on Monday, August 31st. Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a research note on Monday, September 28th. BMO Capital Markets initiated coverage on Prime Medicine in a report on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 price objective for the company. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Prime Medicine in a report on Friday, September 25th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Prime Medicine in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.86.
Check Out Our Latest Analysis on PRME
Prime Medicine Price Performance
The business’s 50-day moving average price is $3.73 and its 200 day moving average price is $3.51.
Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Prime Medicine had a negative return on equity of 286.97% and a negative net margin of 2,497.56%. The company had revenue of $4.21 million during the quarter. On average, analysts predict that Prime Medicine, Inc. will post -0.94 EPS for the current fiscal year.
Institutional Investors Weigh In On Prime Medicine
A number of large investors have recently bought and sold shares of PRME. Bank of America Corp DE acquired a new stake in Prime Medicine in the second quarter valued at approximately $3,621,000. BlackRock Inc. purchased a new position in Prime Medicine during the second quarter worth approximately $35,432,000. Alphabet Inc. acquired a new position in Prime Medicine in the second quarter valued at approximately $61,116,000. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Prime Medicine by 20.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,911,596 shares of the company’s stock worth $8,895,000 after purchasing an additional 498,612 shares during the last quarter. Finally, Redmile Group LLC purchased a new stake in Prime Medicine during the first quarter worth about $5,536,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.
Prime Medicine Company Profile
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
Recommended Stories
- Five stocks we like better than Prime Medicine
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
